source Post navigation Carmot Therapeutics Announces that Preliminary Phase 1 Results Support Once-daily Oral Dosing for its Obesity and Type 2 Diabetes Candidate CT-996 – Yahoo Finance Semaglutide: A New Treatment for Diabetes and Weight Loss – Healthnews.com